Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Trans-2,3-enoyl-CoA reductase pseudogene 1” (TECRP1) does not correspond to a validated or studied gene, protein, or drug target in current scientific knowledge. The only existing molecule with similar nomenclature is the enzyme **trans-2,3-enoyl-CoA reductase** (abbreviation: TECR), which is a multi-pass membrane oxidoreductase located in the endoplasmic reticulum and acts as part of the fatty acid elongation cycle, crucial for the formation of long-chain and very-long-chain fatty acids. The “pseudogene” variant (TECRP1) referenced in the query appears to be a non-existent or uncharacterized, possibly erroneously named or hypothetical entry, and is not a therapeutic target[4][6]. If your intent was to refer to the functional enzyme or gene TECR, see above description and note this is distinct from the queried pseudogene concept. If you require information on known TECR pseudogenes, please provide additional context or alternative names, as TECRP1 does not match any standard entries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on trans-2,3-enoyl-CoA reductase pseudogene 1 (TECRP1).